Literature DB >> 12970424

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.

Silvia Perri1, Catherine E Greer, Kent Thudium, Barbara Doe, Harold Legg, Hong Liu, Raul E Romero, Zequn Tang, Qian Bin, Thomas W Dubensky, Michael Vajdy, Gillis R Otten, John M Polo.   

Abstract

Alphavirus replicon particle-based vaccine vectors derived from Sindbis virus (SIN), Semliki Forest virus, and Venezuelan equine encephalitis virus (VEE) have been shown to induce robust antigen-specific cellular, humoral, and mucosal immune responses in many animal models of infectious disease and cancer. However, since little is known about the relative potencies among these different vectors, we compared the immunogenicity of replicon particle vectors derived from two very different parental alphaviruses, VEE and SIN, expressing a human immunodeficiency virus type 1 p55(Gag) antigen. Moreover, to explore the potential benefits of combining elements from different alphaviruses, we generated replicon particle chimeras of SIN and VEE. Two distinct strategies were used to produce particles with VEE-p55(gag) replicon RNA packaged within SIN envelope glycoproteins and SIN-p55(gag) replicon RNA within VEE envelope glycoproteins. Each replicon particle configuration induced Gag-specific CD8(+) T-cell responses in murine models when administered alone or after priming with DNA. However, Gag-specific responses varied dramatically, with the strongest responses to this particular antigen correlating with the VEE replicon RNA, irrespective of the source of envelope glycoproteins. Comparing the replicons with respect to heterologous gene expression levels and sensitivity to alpha/beta interferon in cultured cells indicated that each might contribute to potency differences. This work shows that combining desirable elements from VEE and SIN into a replicon particle chimera may be a valuable approach toward the goal of developing vaccine vectors with optimal in vivo potency, ease of production, and safety.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970424      PMCID: PMC228391          DOI: 10.1128/jvi.77.19.10394-10403.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

Review 1.  The prime-boost strategy: exciting prospects for improved vaccination.

Authors:  I A Ramshaw; A J Ramsay
Journal:  Immunol Today       Date:  2000-04

2.  Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation.

Authors:  A P Byrnes; D E Griffin
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Antigen levels and antibody titers after DNA vaccination.

Authors:  M Chastain; A J Simon; K A Soper; D J Holder; D L Montgomery; S L Sagar; D R Casimiro; C R Middaugh
Journal:  J Pharm Sci       Date:  2001-04       Impact factor: 3.534

Review 4.  Viruses and interferons.

Authors:  G C Sen
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

5.  Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein.

Authors:  J P Gardner; I Frolov; S Perri; Y Ji; M L MacKichan; J zur Megede; M Chen; B A Belli; D A Driver; S Sherrill; C E Greer; G R Otten; S W Barnett; M A Liu; T W Dubensky; J M Polo
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.

Authors:  N L Davis; I J Caley; K W Brown; M R Betts; D M Irlbeck; K M McGrath; M J Connell; D C Montefiori; J A Frelinger; R Swanstrom; P R Johnson; R E Johnston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism.

Authors:  K D Ryman; W B Klimstra; K B Nguyen; C A Biron; R E Johnston
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

8.  Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.

Authors:  J zur Megede; M C Chen; B Doe; M Schaefer; C E Greer; M Selby; G R Otten; S W Barnett
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

9.  Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5' untranslated region.

Authors:  L J White; J G Wang; N L Davis; R E Johnston
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

10.  Replicon vectors derived from Sindbis virus and Semliki forest virus that establish persistent replication in host cells.

Authors:  S Perri; D A Driver; J P Gardner; S Sherrill; B A Belli; T W Dubensky; J M Polo
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

View more
  68 in total

1.  Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.

Authors:  Soumi Gupta; Ramesh Janani; Qian Bin; Paul Luciw; Catherine Greer; Silvia Perri; Harold Legg; John Donnelly; Susan Barnett; Derek O'Hagan; John M Polo; Michael Vajdy
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 2.  Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments.

Authors:  Philip Wintermeyer; Jack R Wands
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

3.  Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.

Authors:  Elizabeth A Reap; Sergey A Dryga; John Morris; Bryan Rivers; Pamela K Norberg; Robert A Olmsted; Jeffrey D Chulay
Journal:  Clin Vaccine Immunol       Date:  2007-04-18

4.  A novel self-replicating chimeric lentivirus-like particle.

Authors:  Christy K Jurgens; Kelly R Young; Victoria J Madden; Philip R Johnson; Robert E Johnston
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

Review 5.  DNA-launched live-attenuated vaccines for biodefense applications.

Authors:  Peter Pushko; Igor S Lukashevich; Scott C Weaver; Irina Tretyakova
Journal:  Expert Rev Vaccines       Date:  2016-04-25       Impact factor: 5.217

6.  CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.

Authors:  Sandra Lazzaro; Cinzia Giovani; Simona Mangiavacchi; Diletta Magini; Domenico Maione; Barbara Baudner; Andrew J Geall; Ennio De Gregorio; Ugo D'Oro; Cecilia Buonsanti
Journal:  Immunology       Date:  2015-08-28       Impact factor: 7.397

Review 7.  mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Authors:  Giulietta Maruggi; Cuiling Zhang; Junwei Li; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-02-07       Impact factor: 11.454

8.  Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design.

Authors:  Timothy Pepini; Anne-Marie Pulichino; Thomas Carsillo; Alicia L Carlson; Farid Sari-Sarraf; Katrin Ramsauer; Jason C Debasitis; Giulietta Maruggi; Gillis R Otten; Andrew J Geall; Dong Yu; Jeffrey B Ulmer; Carlo Iavarone
Journal:  J Immunol       Date:  2017-04-17       Impact factor: 5.422

Review 9.  A new insight into hepatitis C vaccine development.

Authors:  Chun I Yu; Bor-Luen Chiang
Journal:  J Biomed Biotechnol       Date:  2010-06-13

10.  Comparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in mice.

Authors:  M Jeff Bergen; Chien-Hsiung Pan; Catherine E Greer; Harold S Legg; John M Polo; Diane E Griffin
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.